CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients

被引：25

作者：

Barratt, Daniel T. ^{[1
,2
]}

Cox, Hannah K. ^{[1
]}

Menelaou, Andrew ^{[3
]}

Yeung, David T. ^{[3
,4
,5
]}

White, Deborah L. ^{[3
,5
]}

Hughes, Timothy P. ^{[3
,4
,5
]}

Somogyi, Andrew A. ^{[1
,2
,6
]}

机构：

[1] Univ Adelaide, Adelaide Med Sch, Discipline Pharmacol, Adelaide, SA 5005, Australia

[2] Univ Adelaide, Ctr Personalised Canc Med, Adelaide, SA, Australia

[3] SAHMRI, Adelaide, SA, Australia

[4] SA Pathol, Dept Haematol, Adelaide, SA, Australia

[5] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia

[6] Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA, Australia

来源：

CLINICAL PHARMACOKINETICS | 2017年 / 56卷 / 08期

关键词：

TYROSINE KINASE INHIBITORS; POPULATION PHARMACOKINETICS; TRANSPORTER POLYMORPHISMS; CLINICAL PHARMACOKINETICS; GENETIC POLYMORPHISMS; N-DEMETHYLATION; P-GLYCOPROTEIN; IN-VITRO; CYP3A4; ABCB1;

D O I：

10.1007/s40262-016-0494-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective The aims of this study were to determine the effects of the CYP2C8*3 and *4 polymorphisms on imatinib metabolism and plasma imatinib concentrations in chronic myeloid leukaemia (CML) patients. Methods We genotyped 210 CML patients from the TIDELII trial receiving imatinib 400-800 mg/day for CYP2C8*3 (rs11572080, rs10509681) and *4 (rs1058930). Steady-state trough total plasma N-desmethyl imatinib (major metabolite):imatinib concentration ratios (metabolic ratios) and trough total plasma imatinib concentrations were compared between genotypes (one-way ANOVA with Tukey post hoc). Results CYP2C8*3 (n = 34) and *4 (n = 15) carriers had significantly higher (P < 0.01) and lower (P < 0.01) metabolic ratios, respectively, than CYP2C8*1/*1 (n = 147) patients (median +/- standard deviation: 0.28 +/- A 0.08, 0.18 +/- A 0.06 and 0.22 +/- A 0.08, respectively). Plasma imatinib concentrations were consequently > 50% higher for CYP2C8*1/*4 than for CYP2C8*1/*1 and CYP2C8*3 carriers (2.18 +/- 0.66 vs. 1.45 +/- 0.74 [P < 0.05] and 1.36 +/- 0.98 mu g/mL [P < 0.05], respectively). Conclusions CYP2C8 genotype significantly alters imatinib metabolism in patients through gain- and loss-of-function mechanisms.

引用

页码：977 / 985

页数：9

共 49 条

[11] Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response [J].

Filppula, Anne M. ;

Neuvonen, Mikko ;

Laitila, Jouko ;

Neuvonen, Pertti J. ;

Backman, Janne T. .

DRUG METABOLISM AND DISPOSITION, 2013, 41 (01) :50-59

[12]

Fox J, 2003, J STAT SOFTW, V8, P1, DOI [DOI 10.18637/JSS.V008.I15, 10.18637/jss.v008.i15]

[13]

Fox J., 2018, An R Companion to Applied Regression

[14] Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed? [J].

Gandia, Peggy ;

Arellano, Cecile ;

Lafont, Thierry ;

Huguet, Francoise ;

Malard, Laurence ;

Chatelut, Etienne .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) :531-536

[15] Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions [J].

Gao, Yiwen ;

Liu, Duan ;

Wang, Huijuan ;

Zhu, Juanli ;

Chen, Chao .

XENOBIOTICA, 2010, 40 (07) :467-475

[16] Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia [J].

Gater, Adam ;

Heron, Louise ;

Abetz-Webb, Linda ;

Coombs, John ;

Simmons, Jeff ;

Guilhot, Francois ;

Rea, Delphine .

LEUKEMIA RESEARCH, 2012, 36 (07) :817-825

[17] Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions [J].

Gotta, Verena ;

Bouchet, Stephane ;

Widmer, Nicolas ;

Schuld, Peter ;

Decosterd, Laurent A. ;

Buclin, Thierry ;

Mahon, Francois-Xavier ;

Csajka, Chantal ;

Molimard, Mathieu .

LEUKEMIA RESEARCH, 2014, 38 (07) :764-772

[18] Metabolism and disposition of imatinib mesylate in healthy volunteers [J].

Gschwind, HP ;

Pfaar, U ;

Waldmeier, F ;

Zollinger, M ;

Sayer, C ;

Zbinden, P ;

Hayes, M ;

Pokorny, R ;

Seiberling, M ;

Ben-Am, M ;

Peng, B ;

Gross, G .

DRUG METABOLISM AND DISPOSITION, 2005, 33 (10) :1503-1512

[19] Imatinib disposition and ABCB1 (MDR1, p-glycoprotein) genotype [J].

Gurney, H. ;

Wong, M. ;

Balleine, R. L. ;

Rivory, L. P. ;

McLachlan, A. J. ;

Hoskins, J. M. ;

Wilcken, N. ;

Clarke, C. L. ;

Mann, G. J. ;

Collins, M. ;

Delforce, S-E ;

Lynch, K. ;

Schran, H. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (01) :33-40

[20] Simultaneous inference in general parametric models [J].

Hothorn, Torsten ;

Bretz, Frank ;

Westfall, Peter .

BIOMETRICAL JOURNAL, 2008, 50 (03) :346-363

← 1 2 3 4 5 →